pnb-0408 dihexa human trial Dihexa (also known as PNB-0408) is an experimental small molecule derived from angiotensin IV. It was engineered to cross the blood–brain barrier and has shown synaptogenic effects Dihexa UK: Evidence-Based Peptide Research

Nie suy do wyliczania dawek, przygotowywania iniekcji ani ustalania sposobu stosowania substancji u ludzi lub zwierzt

A common protocol involves administering 1,000 mcg of B12 weekly for 4 to 8 weeks, depending on the deficiencys severity and the patients response

Companies choose Paragraph III when they judge that the listed patent is robust enough that a Paragraph IV challenge is unlikely to succeed, when the commercial value does not justify the litigation cost, or when they want to queue up an approval that will be immediately effective on the expiration date

1 mg equals 1000 mcg

Tissue cultures were negative